# Creabilis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/creabilis

- Industry: Pharmaceuticals
- Headquarters: Canterbury, UK
- Website: www.creabilis-sa.com
- Total disclosed funding: $52M
- Latest round: Series B (Oct 4, 2011)
- Investors on record: 3

## About

Creabilis SA is a biopharmaceutical company focused on developing innovative therapeutics for rare diseases. It leverages advanced technologies to create solutions that address unmet medical needs in targeted patient populations.Creabilis SA, founded in 2003 in Canterbury, UK, specializes in biopharmaceutical development. The company was acquired by Sienna Biopharmaceuticals, Inc. in December 2016, though the financial terms of the transaction were not disclosed. Creabilis has completed 3 deals, with the latest being a Series B round in which they raised EUR 15.00 mn led by AbbVie Biotech Ventures, alongside investors NeoMed and Sofinnova Partners. The total amount raised by the company is EUR 15.00 mn.Creabilis SA focuses on the development of innovative therapeutics specifically designed for rare diseases. Their product pipeline includes several advanced biopharmaceuticals aimed at providing effective treatments to patients with unique medical needs, ensuring compatibility with existing healthcare infrastructures.In the most recent year, Creabilis SA reported no revenue, with an EBITDA of EUR -970,121.60 for 2016.Looking ahead, Creabilis SA aims to expand its product offerings and enter new markets. The recent funding from the Series B round will be utilized to support the development of new therapeutics and enhance existing solutions. Additionally, the company targets increased market presence in Europe and North America by 2020. The acquisition by Sienna Biopharmaceuticals, Inc. will likely facilitate broader access to resources and expertise, aiding in these strategic initiatives.

## Funding rounds

- Series B, Oct 4, 2011, $21M — Sofinnova Partners, NeoMed, AbbVie Ventures
- Series A, Jun 6, 2008, $32M — Sofinnova Partners, NeoMed

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B
- NeoMed (https://capitalatlas.ai/funds/neomed) — Series A, Series B
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Series B